Pharmacy, Health Sciences & Exercise Science
Evaluation of the Safety and Efficacy of the New Oral Anticoagulants versus Warfarin in Patients Getting an AV Node Ablation
Document Type
Oral Presentation
Location
Indianapolis, IN
Subject Area
Pharmacy, Health Sciences & Exercise Science
Start Date
11-4-2014 8:30 AM
End Date
11-4-2014 10:00 AM
Sponsor
Alex Ansara (Butler University)
Description
Background: Over three million Americans have been diagnosed with atrial fibrillation. This dangerous condition increases the risk of heart failure and risk of death due to stroke. Embolic stroke, which is debilitating in almost 50% of patients, is the most feared complication of atrial fibrillation and can be effectively decreased by 68% with anticoagulation. Rate control and anticoagulation are two necessary approaches to managing atrial fibrillation. Drugs approved by the Food and Drug Administration for stroke prevention in atrial fibrillation include warfarin, dabigatran, rivaroxaban, apixaban, and aspirin. The CHEST guidelines currently have no recommendations for the use of the dabigatran, rivaroxaban, and apixaban in patients undergoing AV nodal ablation. Catheter ablation of the atrioventricular node has evolved into a mainstream treatment for atrial fibrillation in patients that either can't tolerate medications or do not respond to medications. This procedure uses radiofrequency energy to destroy a small area of heart tissue that leads to rapid and irregular atrial and ventricular tachycardias.
Study objective: The objective is to compare the safety and efficacy of the new oral anticoagulants versus warfarin in patients getting an AV node ablation.
Hypothesis: There is no statistically significant difference in the incidence of hospital readmission within 30 days and bleeding events of patients getting an AV node ablation who are receiving warfarin versus dabigatran, rivaroxaban or apixaban. But oral anticoagulants such as dabigatran, rivaroxaban or apixaban will reduce the risk of stroke.
Methods: A retrospective chart review of patients undergoing AV node ablation and receiving antithrombotic therapy will be conducted. Patient charts will be reviewed to compare the incidence of hospital readmission within 30 days, stroke, and bleeding events. Statistical analysis will be conducted in order to compare event rates.
Significance: The goal of the study is to determine whether new oral anticoagulants are safer and more effective alternatives to warfarin for stroke prevention in the setting of AV node ablation.
Evaluation of the Safety and Efficacy of the New Oral Anticoagulants versus Warfarin in Patients Getting an AV Node Ablation
Indianapolis, IN
Background: Over three million Americans have been diagnosed with atrial fibrillation. This dangerous condition increases the risk of heart failure and risk of death due to stroke. Embolic stroke, which is debilitating in almost 50% of patients, is the most feared complication of atrial fibrillation and can be effectively decreased by 68% with anticoagulation. Rate control and anticoagulation are two necessary approaches to managing atrial fibrillation. Drugs approved by the Food and Drug Administration for stroke prevention in atrial fibrillation include warfarin, dabigatran, rivaroxaban, apixaban, and aspirin. The CHEST guidelines currently have no recommendations for the use of the dabigatran, rivaroxaban, and apixaban in patients undergoing AV nodal ablation. Catheter ablation of the atrioventricular node has evolved into a mainstream treatment for atrial fibrillation in patients that either can't tolerate medications or do not respond to medications. This procedure uses radiofrequency energy to destroy a small area of heart tissue that leads to rapid and irregular atrial and ventricular tachycardias.
Study objective: The objective is to compare the safety and efficacy of the new oral anticoagulants versus warfarin in patients getting an AV node ablation.
Hypothesis: There is no statistically significant difference in the incidence of hospital readmission within 30 days and bleeding events of patients getting an AV node ablation who are receiving warfarin versus dabigatran, rivaroxaban or apixaban. But oral anticoagulants such as dabigatran, rivaroxaban or apixaban will reduce the risk of stroke.
Methods: A retrospective chart review of patients undergoing AV node ablation and receiving antithrombotic therapy will be conducted. Patient charts will be reviewed to compare the incidence of hospital readmission within 30 days, stroke, and bleeding events. Statistical analysis will be conducted in order to compare event rates.
Significance: The goal of the study is to determine whether new oral anticoagulants are safer and more effective alternatives to warfarin for stroke prevention in the setting of AV node ablation.